



**Jean-François Dufour**

**Kontakt**

Jean-François Dufour

## Publikationen (24)

Negro F, Muellhaupt B, Semela D, Blach S, Bruggmann P, De Gottardi A, Dufour J, Fraga M, Galante A, Razavi H, Vieira Barbosa J, Razavi-Shearer D. The current and future burden of hepatitis B in Switzerland: a modelling study. *Swiss Med Wkly* 2023; 153:40086.

Bihl F, Semmo N, Semela D, Scheidegger C, Razavi H, Negro F, Mullhaupt B, Lavanchy D, Dufour J, Castro Batanjer E, Bruggmann P, Blach S. HCV disease burden and population segments in Switzerland. *Liver Int* 2021

Goossens N, Semela D, Razavi H, Negro F, Muellhaupt B, Moriggia A, Mertens J, Jornayaz F, Dufour J, Cerny A, Bellentani S, Estes C. Nonalcoholic fatty liver disease burden – Switzerland 2018–2030. *Swiss Med Wkly* 2019; 149:w20152.

Geier A, Mullhaupt B, Bischoff-Ferrari H, Saleh L, Marques Maggio E, Jahn D, Bantel H, Tschopp O, Seifert B, Tay F, Semela D, Stirnimann G, Eichinger M, Dufour J. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. *Scand J Gastroenterol* 2018;1-7.

Quteineh L, Mohacsi P, Dufour J, Soccal P, Katalik Z, Marques-Vidal P, Vollenweider P, Recher M, Hess C, Pascual M, Eap C, Steiger J, Van Delden C, Wójtowicz A, Bochud P, Crettol S, Vandenberghe F, Venetz J, Manuel O, Golshayan D, Lehmann R, Mueller N, Binet F, Swiss Transplant Cohort Study. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. *Am J Transplant* 2018; 19:238–246.

Saigi-Morgui N, Eap C, Pascual M, Soccal P, Dufour J, Mohacsi P, Steiger J, Van Delden C, Binet F, Mueller N, Katalik Z, Crettol S, Bochud P, Quteineh L, Swiss Transplant Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. *Pharmacogenomics J* 2017

Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour J. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. *J Hepatol* 2017; 67:876–878.

Wang H, Pichulik T, Mullhaupt B, Semela D, Dufour J, Bochud P, Bowie A, Kalinke U, Berg T, Weber A, Wiese M, Löffler M, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery S, Filomena A, Wolz O, Schneiderhan-Marra N, East-German and Swiss Hepatitis C Virus Study Groups. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. *Hepatology* 2015; 62:1375–87.

Lange C, Negro F, Semela D, Katalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud P, Hiroshima Liver Study Group, Mullhaupt B, Malinvernì R, Heim M, Miki D, Ochi H, Nischalke H, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour J, Gorgievski-Hrisoho M, Swiss Hepatitis C Cohort Study Group. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. *PloS one* 2013; 8:e64053.

Lange C, Bochud P, Katalik Z, Moradpour D, Semela D, Negro F, Mullhaupt B, Malinvernì R, Kaiser L, Heim M, Cerny A, Cellera C, Dufour J, Bibert S, Swiss Hepatitis C Cohort Study Group. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. *J Hepatol* 2013; 59:504–9.

Rau M, Geier A, Mullhaupt B, Semela D, Moradpour D, Dufour J, Dill M, Schmitt J, Weisskopf M, Becker P, Manser C, Russmann S, Stickel F, Swiss Hepatitis C Cohort Study Group (SCCS). Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. *J Hepatol* 2012; 58:669–75.

Kuske L, Dufour J, Cerny A, Malinvern R, Heim M, Malé P, Moradpour D, Semela D, Negro F, Mullhaupt B, Mensen A, Swiss Hepatitis C Cohort Study. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. *Swiss Med Wkly* 2012; 142:w13651.

Patin E, Stewart G, Booth D, George J, Casanova J, Bréchot C, Rice C, Talal A, Jacobson I, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud P, Abel L, Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium, Suppiah V, Martinetti G, Hirsch H, Katalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Mullhaupt B, Semela D, Dufour J, Heim M, Moradpour D, Cerny A, Malinvern R, French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology* 2012; 143:1244-52.e1-12.

Rauch A, Hirschel B, Malinvern R, Moradpour D, Mullhaupt B, Witteck A, Beckmann J, Berg T, Bergmann S, Negro F, Telenti A, Bochud P, Swiss Hepatitis C Cohort Study, Heim M, Günthard H, Furrer H, Katalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour J, Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010; 138:1338-45, 1345.e1-7.

Bochud P, Negro F, Francioli P, Malinvern R, Cerny A, Moradpour D, Heim M, Borovicka J, Mullhaupt B, Dufour J, Bochud M, Overbeck K, Cai T, Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *Journal of hepatology* 2009; 51:655-66.

Piguet A, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C, St-Pierre M, Dufour J. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. *J Hepatol* 2008; 49:78-87.

Chtiou H, Semela D, Ledermann M, Zimmermann A, Dufour J. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. *Liver Int* 2007; 27:764-71.

Semela D, Piguet A, Kolev M, Schmitter K, Hlushchuk R, Djonov V, Stoupis C, Dufour J. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. *J Hepatol* 2007; 46:840-8.

Martin J, Thorgeirsson S, Brenner C, Cassio D, Ziemiecki A, St-Pierre M, Semela D, Lee J, Piguet A, Schmidt K, Magnino F, Dufour J. Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. *Gastroenterology* 2006; 130:2179-88.

Semela D, Dufour J. Angiogenesis and hepatocellular carcinoma. *J Hepatol* 2004; 41:864-80.

Redaelli C, Semela D, Carrick F, Ledermann M, Candinas D, Sauter B, Dufour J. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. *J Hepatol* 2004; 40:305-12.

Vashist Y, Semela D, Dufour J. Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. *Med Hypotheses* 2004; 62:82-5.

August-Jörg B, Renner E, Weitz M, Meyenberger C, Hermann R, Henz S, Gonvers J, Dufour J, Borovicka J, Swiss Association for the Study of the Liver. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2003; 133:455-60.

Helbling B, Renner E, Sagmeister M, Borovicka J, Steuerwald M, Cathomas G, Reichen J, Dufour J, Gonvers J, Viani F, Stamenic I, Investigators of the Swiss Association for the Study of the Liver. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. *Hepatology* (Baltimore, Md.) 2002; 35:447-54.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen      Rorschacher Strasse 95      CH-9007 St.Gallen      T: +41 71 494 11 11      support.forschung@kssg.ch